TPO

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	6

63. 特発性血小板減少性紫斑病

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

trials per page:

Showing 1 to 6 of 6 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05718856 (ClinicalTrials.gov)	April 1, 2023	13/11/2022	TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Prima ...	A Multicenter, Randomized, Open-label StudyTo Compare The Efficacy And Safety Of TPO-RAs Combining A ...	Primary Immune Thrombocytopenia (ITP)	Drug: TPO-RAs;Drug: TPO-RAs combining anti-CD 20 monoclonal antibody	Institute of Hematology & Blood Diseases Hospital	Beijing Children's Hospital;Tianjin People's Hospital;The Second Affiliated Hospital of Kunming Medi ...	Not yet recruiting	6 Years	17 Years	All	166	Phase 4	China
2	NCT04890041 (ClinicalTrials.gov)	May 30, 2021	12/5/2021	TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years	Efficacy of TPO-RA in the Management of Primary Immune Thrombocytopenia (ITP) in Patients Older Than ...	Primary Immune Thrombocytopenic Purpura	Drug: TPO-RA	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	14 Years	N/A	All	100	N/A	China
3	ChiCTR2000039630	2021-01-01	2020-11-03	Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists fo ...	Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists fo ...	Primary immune thrombocytopenia	experimental group:Montelukast sodium 10mg/day; rhTPO 15000 units;control group:rhTPO 15000 units;	Department of Hematology, Second Medical Center, Chinese PLA General Hospital	NULL	Recruiting	14	80	Both	experimental group:51;control group:51;	Phase 2	China
4	NCT04214951 (ClinicalTrials.gov)	January 1, 2020	28/12/2019	A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia	A Prospective Observational Study of Switching Eltrombopag and Recombinant Human Thrombopoietin In P ...	Corticosteroid-resistant or Relapsed ITP	Drug: Eltrombopag;Drug: Recombinant human thrombopoietin (rh-TPO)	Peking University People's Hospital	NULL	Active, not recruiting	18 Years	75 Years	All	100		China
5	NCT04089267 (ClinicalTrials.gov)	December 2016	10/9/2019	Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatme ...	Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Diff ...	ITP	Drug: TPO	Shenyang Sunshine Pharmaceutical Co., LTD.	NULL	Completed	18 Years	N/A	All	288	Phase 4	China
6	NCT01506414 (ClinicalTrials.gov)	June 2009	16/11/2011	Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)	A Multicentre Investigation of Recombinant Human Thrombopoietin (Rh-TPO) Combine With Low-dose Ritux ...	Purpura;Idiopathic Thrombocytopenic Purpura	Drug: rhTPO in combination with Rituximab	Ming Hou	Peking Union Medical College Hospital;Chinese Academy of Medical Sciences;First Affiliated Hospital, ...	Completed	16 Years	75 Years	Both	91	Phase 3	China

First Previous1Next Last